Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongchang Qu

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Molecular Metabolism|December 14, 2025
Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studiesWilliam Roell, Jorge Alsina-Fernandez, Hongchang Qu, et al.
Molecular Metabolism|October 18, 2025
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of conceptDaniel A Briere, Hongchang Qu, Katherine Lansu, et al.
Cell Metabolism|August 19, 2022
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of conceptTamer Coskun, Shweta Urva, William C Roell, et al.
Circulation Research|March 30, 2012
Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitisHarald F Langer, Eun Young Choi, Hong Zhou, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Molecular Metabolism|December 14, 2025
Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studiesWilliam Roell, Jorge Alsina-Fernandez, Hongchang Qu, et al.
Molecular Metabolism|October 18, 2025
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of conceptDaniel A Briere, Hongchang Qu, Katherine Lansu, et al.
Cell Metabolism|August 19, 2022
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of conceptTamer Coskun, Shweta Urva, William C Roell, et al.
Circulation Research|March 30, 2012
Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitisHarald F Langer, Eun Young Choi, Hong Zhou, et al.
Pageof 4